Hyperuricemia after orthotopic liver transplantation: divergent associations with progression of renal disease, incident end-stage renal disease, and mortality by unknown
RESEARCH ARTICLE Open Access
Hyperuricemia after orthotopic liver
transplantation: divergent associations with
progression of renal disease, incident end-
stage renal disease, and mortality
Joseph C. Longenecker1,2, Sana Waheed3, Ghassan Bandak4, Christine A. Murakami5, Blaithin A. McMahon2,
Allan C. Gelber2 and Mohamed G. Atta2*
Abstract
Background: Although hyperuricemia is common after orthotopic liver transplantation (OLT), its relationship to
mortality, progressive kidney disease, or the development of end stage renal disease (ESRD) is not well-described.
Methods: Data from 304 patients undergoing OLT between 1996 and 2010 were used to assess the association of
mean serum uric acid (UA) level in the 3-months post-OLT with mortality, doubling of creatinine, and ESRD
incidence. Post-OLT survival to event outcomes according to UA level and eGFR was assessed using the Kaplan
Meier method and multivariate Cox proportional hazards models.
Results: Mean UA level among the 204 patients with an eGFR level ≥60 ml/min/1.73 m2 was 6.4 mg/dl compared
to 7.9 mg/dl among the 100 patients with eGFR <60 (p < 0.0001). During a median of 4.6 years of follow-up,
mortality rate, doubling of creatinine, and ESRD incidence were 48.9, 278.2, and 20.7 per 1000 person-years,
respectively. In the first 5 years of follow-up, elevated UA was associated with mortality (Hazard Ratio, HR = 1.7; p =
0.045). However, among those with eGFR ≥ 60, UA level did not predict mortality (HR = 1.0; p = 0.95), and among
those with eGFR < 60, elevated UA was a strong predictor of mortality (HR = 3.7[1.1, 12.0]; p = 0.03). UA was not
associated with ESRD, but was associated with doubling of creatinine among diabetics (HR = 2.2[1.1, 4.3]; p = 0.025).
Conclusion: In this post-OLT cohort, hyperuricemia independently predicted mortality, particularly among patients
with eGFR < 60, and predicted doubling of creatinine among diabetics.
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Background
Hyperuricemia is a common occurrence after organ
transplantation, [1] with a high prevalence after cardiac/
lung transplantation (70–80%), [2] renal transplantation
(30–40%), [1] and liver transplantation (14 to 47%) [3].
Uric acid (UA) is handled in the kidney by membrane
transport proteins in the proximal tubules [4]. Therefore,
hyperuricemia often accompanies declining renal func-
tion, both of which are commonly seen in the post-OLT
population [5].
Several studies have reported an association be-
tween hyperuricemia and cardiovascular mortality in
the general population [6, 7], and in patients with
chronic kidney disease (CKD) [8]. General population
studies have also reported that hyperuricemia is pro-
spectively associated with worsening renal disease and
progression to ESRD [9]. However, a recent study of
patients with moderate to severe CKD found that hy-
peruricemia is not prospectively associated with de-
cline in renal function [10].
In the liver transplant population, some studies have
suggested that hyperuricemia in the post-transplant
period may be an independent predictor of renal disease
after orthotropic liver transplantation (OLT) [11].
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Furthermore, the treatment of hyperuricemia in liver
transplant recipients is associated with an improvement
in kidney function, suggesting that uric acid may be a
cause of renal disease in this population [3]. Small stud-
ies in non-transplant populations have also found that
allopurinol lowers blood pressure, reduces left ventricu-
lar hypertrophy and preserves renal function [12, 13].
Although hyperuricemia has been associated with in-
creased mortality in the post-renal transplantation
period, [14, 15] little is known about the impact of hy-
peruricemia on mortality and progression of renal dis-
ease in the post-liver transplantation period, particularly
in those with concomitant CKD. The objective of this
cohort study is to assess hyperuricemia and its prospect-
ive association with mortality, doubling of creatinine,
and progression to ESRD among orthotopic liver trans-
plant recipients.
Methods
This non-concurrent cohort study included 304 patients
who underwent first OLT between January, 1996, and
February, 2009, at a single U.S. tertiary hospital with an
active liver transplantation program. Exclusion criteria
included age <18 years, transplantation of multiple or-
gans, and status 1A liver failure. Of 481 OLT patients
eligible for inclusion in the study, 304 patients had
serum uric acid measurements obtained during the 90-
day period after OLT. Four patients who had been en-
rolled in the Medicare dialysis program before OLT were
excluded from the analysis of ESRD incidence and doub-
ling of creatinine (n = 300). The study protocol was ap-
proved by the Johns Hopkins School of Medicine
Institutional Review Board.
Clinical data were obtained by medical record review,
including demographic factors, liver disease etiology,
and co-morbid conditions (all defined by documentation
in the medical record). Uric acid and serum creatinine
levels assayed by the John Hopkins Hospital Laboratory
using standard clinical laboratory techniques were re-
trieved from the laboratory database. The Model for
End-Stage Liver Disease (MELD) score at OLT was cal-
culated in accordance with the United Network for
Organ Sharing (UNOS) formula [16]. To calculate the
MELD score, serum bilirubin, creatinine, and Inter-
national Normalized Ratio (INR) values less than 1.0
were set to 1.0 to preclude negative values, and serum
creatinine upper-limit values were set at 4.0 if the pa-
tient required renal replacement therapy prior to trans-
plantation. Renal function was assessed by estimating
glomerular filtration rate (eGFR) using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
formula [17]. Categories of eGFR were created according
to standard classifications [18]. Information regarding
the primary calcineurin inhibitor (CNI) used after
transplantation was obtained in 2015 from a review of
electronic discharge summaries for the OLT admission.
However, discharge summaries for admissions before
2003 were not available. Therefore, for those admissions,
the type of CNI in use during 2003/4 was recorded, if
available.
Three primary study outcomes included total mortal-
ity, doubling of creatinine, and ESRD incidence from
time of OLT with follow-up through April 30, 2010. The
primary exposure variable was the mean of all UA levels
obtained during the 3 months after OLT. For partici-
pants with death (n = 5) or an ESRD event (n = 7) that
occurred during the 3 months post-OLT, the mean uric
acid level between OLT and the event was used. A total
of 3425 uric acid levels obtained during the 3 months
after OLT were available for analysis. A median of 4
[IQR: 2–9; Mean: 11] uric acid measurements were
available per patient. Doubling of creatinine was defined
as attaining a creatinine level more than twice the nadir
creatinine level within the first 90 days post-OLT. For
women with a nadir creatinine level <0.5 mg/dl and men
<0.6 mg/dl, the nadir creatinine level was set to 0.5 mg/
dl and 0.6 mg/dl, respectively.
Vital status was assessed using data from the National
Death Index, electronic medical record, and UNOS
registry. Time to death was assessed as time from OLT
to death. Data on occurrence of end stage renal disease,
as measured by enrollment in the Medicare dialysis pro-
gram, were obtained by linkage of the clinical dataset to
the United States Renal Data System (USRDS).
Statistical analysis
Data were analyzed using Stata/SE 12 (StataCorp, Col-
lege Station, TX). The Student t-test and Analysis of
Variance (ANOVA) were used to assess unpaired associ-
ations between continuous and categorical variables,
where appropriate. A two-sided p-value of less than 0.05
was considered significant. Survival analysis was used to
assess the association of the mean uric acid level during
the 3 months post-OLT with time to death and time to
ESRD incidence. Incidence rates, 95% confidence inter-
vals, and significance levels were generated using the
Stata stset, stptime and stir commands. The Kaplan-
Meier product limit estimator function was used to as-
sess survival according to uric acid level, dichotomized
at 6.5 mg/dl. We chose the same uric acid cut-point for
male and female patients since the median uric acid level
essentially equalized in this population and did not differ
significantly according to gender in the 3 months after
OLT. The log-rank and Breslow tests were used to assess
statistical significance between survival curves. Cox pro-
portional hazards models were constructed (with time
from OLT to death, doubling of creatinine, or ESRD as
dependent variables) to estimate unadjusted and
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adjusted hazard ratios (HR) of all-cause mortality and
ESRD following transplantation and related 95% confi-
dence intervals (95% CI). For the mortality analyses,
multivariate Cox regression models adjusted for age, sex,
and eGFR level after OLT, the latter as a time-varying
covariate for 12 months after OLT (diabetes was not as-
sociated with total mortality, and therefore was not in-
cluded in the mortality models). For the doubling of
creatinine and ESRD incidence analyses, the same ap-
proach was used, except that diabetes was also included
as a clinically-important covariate. A priori analyses
stratified by baseline pre-OLT eGFR level (mean eGFR
over the 14 days prior to OLT, dichotomized at 60 mg/
min/1.73 m2) were performed for the mortality, doubling
of creatinine, and ESRD outcomes, and an interaction
term (uric acid X eGFR level) was entered into the
models to test the statistical significance of interaction.
Additionally, for the doubling of creatinine and ESRD
analyses, a priori stratification by diabetes with a corre-
sponding test for interaction (uric acid X diabetes) was
conducted. All models adhered to the proportionality as-
sumption, as assessed by Schoenfeld residuals, a global
test of proportionality, and log-log survival plots.
Results
The mean age was 51.5 years, and 65.5% of the trans-
plant recipients were male (Table 1). Approximately 60%
of OLT patients had a MELD score below 20; 68% had
an eGFR ≥60 ml/min/1.73 m2, and 28% were diabetic.
To assess the representativeness of the 304 patients in-
cluded in this study, comparison was made with the eli-
gible patients (n = 177) who similarly underwent OLT
during the same calendar period but did not have any
uric acid levels measured during the 3-month period
after OLT. The study group was comparable to the
group without uric acid values with respect to mean age
(52 vs. 52, respectively), male sex (66% vs. 68%), white
race (71% vs. 74%), prevalent diabetes (28% vs. 27%),
hypertension (19% vs. 25%), and median eGFR during
the year after OLT (70 vs. 67 ml/min/1.73 m2). These
findings suggest the 304 patients included in the study
are reasonably representative of the 481 eligible OLT
patients.
The overall mean (±s.d.) uric acid level was 6.9 (±2.3)
mg/dl., and the median [interquartile range] was 6.6
[5.3, 8.4] mg/dl (Table 2). Uric acid was strongly associ-
ated with lower eGFR in the 3-month period after OLT.
Although older age, white race, higher MELD score,
hypertension, and presence of Hepatitis C were all asso-
ciated with higher uric acid levels, these associations did
not reach statistical significance. Other characteristics
were not associated with uric acid level.
The mean (and median) uric acid levels among the
204 patients with an eGFR level ≥60 mg/min/1.73 m2
Table 1 Demographic and clinical characteristics at time of liver




≤ 45 58 (19.1)
46–54 134 (44.1)
≥ 55 112 (36.8)
Mean age (±s.d.) 51.5 (±9.4)











Pre-MELD era (before 2/2002) 151 (49.7)
MELD era (after 2/2002) 153 (50.3)
MELD score category




≥ 40 6 (2.0)
Mean MELD Score (±s.d.) 20.3 (±7.6)
eGFR Category at Tx
≥ 90 138 (46.0)
60–89 66 (22.0)
30–59 65 (21.7)
< 30 31 (10.3)
Mean Pre-Tx eGFR-Epi (±s.d.) 79.4 (±34.5)
Hepatorenal syndrome 20 (6.9)
Hemodialyzed before OLT Transplantation 8 (2.8)
Hemodialyzed after OLT 13 (4.5)
Diabetes 79 (27.5)
Hypertension 55 (19.4)
Hepatitis C Virus 139 (48.1)
Hepatocellular Carcinoma 22 (7.2)







Type not known 72 (23.7)
Longenecker et al. BMC Nephrology  (2017) 18:103 Page 3 of 11
was 6.4 mg/dl (median, 6.1 mg/dl), compared to 7.9 mg/
dl (median, 7.6 mg/dl) among the 100 patients with
eGFR <60 mg/min/1.73 m2 (p < 0.001), illustrating a
strong association between eGFR at the time of OLT and
uric acid level (Fig. 1).
Uric acid level and survival
During a median of 4.6 years of follow up [minimum,
1 month; maximum, 14.0 years] and a total of 1819
person-years of follow-up from the date of OLT, 89 deaths
occurred. Through April, 2010, follow-up mortality data
was complete, being assessed through the National Death
Index and UNOS registry. The overall crude mortality rate
was 48.9 deaths per 1000 person-years [95% confidence
interval, 39.7–60.2 deaths/person-years].
The unadjusted mortality rate (Table 3) was higher
among those with an elevated uric acid (58.0 deaths per
1000 person-years) than those with a lower uric acid
(39.8 deaths per 1000 person-years; p = 0.04). A Kaplan-
Meier curve of survival according to uric acid level
shows early separation (Fig. 2, Panel A), and later nar-
rowing of the two uric acid level curves (Breslow p-
value = 0.04). A Kaplan-Meier curve truncated at 5 years
of follow-up demonstrates significant separation of the
two curves (Log-rank p-value = 0.03). After adjusting for
age, gender, and time-varying eGFR level, the overall
hazard ratio (HR) of death, while of moderate magnitude
(HR = 1.4; confidence interval, C.I. [0.9–2.2]), was not
Table 2 Mean serum uric acid levels in the 3-month period
after liver transplantation, according to patient characteristics
Mean serum uric acid (mg/dl)
Characteristic n Mean (±SD) P
All 304 6.9 (±2.3)
[median, 6.6]
Age (years) 0.08
≤ 50 119 6.6 (±2.3)
> 50 185 7.1 (±2.3)
Gender 0.28
Male 199 7.0 (±2.3)
Female 105 6.7 (±2.3)
Race 0.07
White 216 7.1 (±2.3)
Black/Other 88 6.6 (±2.3)
MELD era 0.27
Before 2/2002 151 6.8 (±2.2)
After 2/2002 153 7.1 (±2.3)
eGFR Categorya at Tx <0.0001
≥ 90 138 6.0 (±2.0)
60–89 66 7.3 (±2.0)
30–59 65 8.0 (±2.4)
< 30 31 7.9 (±2.1)
MELD score category 0.052
< 20 177 6.7 (±2.2)
20–29 85 7.4 (±2.3)
≥ 30 38 7.1 (±2.1)
Diabetes 0.18
No 208 6.8 (±2.2)
Yes 79 7.2 (±2.4)
Hypertension 0.06
No 228 6.8 (±2.3)
Yes 55 7.4 (±2.4)
Hepatitis C Virus 0.06
No 150 6.7 (±2.4)
Yes 139 7.2 (±2.1)
Mycophenolate mofetil 0.63
No 124 6.8 (±2.4)
Yes 145 6.9 (±2.2)
Steroids 0.73
No 21 7.1 (±2.2)
Yes 259 6.9 (±2.3)
Calcineurin inhibitor 0.61
Tacrolimus 204 6.9 (±2.3)
Cyclosporine 20 6.7 (±2.7)
None 8 7.6 (±2.1)
Type not known 72 6.9 (±2.1)
a Units, ml/min/1.73 m2
Fig. 1 Histograms of uric acid level, according to estimated
glomerular filtration rate (eGFR) level, according to eGFR level ≥60
ml/min (Panel a) and <60 ml/min (Panel b)
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statistically significant (p = 0.11). However, when trun-
cated at 5 years of follow-up, the adjusted association
becomes significant (HR = 1.7; C.I. [1.0, 2.8]; p = 0.045).
Table 3 also presents a stratified analysis which demon-
strates a statistically significant interaction between high
uric acid level and low eGFR (p-interaction = 0.046). Among
those with eGFR ≥ 60 ml/min/1.73 m2, uric acid level does
not predict mortality (HR = 1.0; p = 0.95). However, among
those with an eGFR < 60, a high uric acid level strongly
and significantly predicts mortality (HR = 3.7; p = 0.03).
This finding is also confirmed in the unadjusted stratified
analysis of mortality rates (Table 3) and the Kaplan-Meier
curves shown in Panels B and C of Fig. 2.
When uric acid was entered into the multivariate model
as a continuous variable, it was not associated with mor-
tality among those with a high eGFR. In contrast, a 1 mg/
dl higher level of serum uric acid was strongly associated
with mortality (HR = 1.2 [1.1, 1.4]; p = 0.008) among those
with a low eGFR (Table 3). The p-value for interaction
in the model with uric acid as a continuous variable
was p-interaction = 0.01. When uric acid level was cate-
gorized into quartiles (results not shown), none of the
estimates was statistically significant, likely owing to
insufficient power resulting from the smaller number
of deaths in each category, especially among those
with lower eGFR and lower uric acid levels.
Uric acid level and doubling of creatinine
A total of 180 (60%) participants experienced a doubling
of creatinine over 731 person-years and a median of
0.93 years to event or censoring. The overall incidence
rate was 278.2 events/1000 person-years. In the entire co-
hort, elevated uric acid level (either dichotomized or con-
tinuous) was not associated with doubling of creatinine
(Table 4). However, UA was associated with doubling of
creatinine among diabetics (HR = 2.2; p = 0.025), but not
among non-diabetics (HR = 0.8; p = 0.15; p-interaction =
0.061). Similar effect modification by diabetes was seen in
the crude analysis of incidence rates (Table 4) and with
Kaplan-Meier plots (Fig. 3). There was no interaction ac-
cording to baseline eGFR level (p-interaction = 0.38).
Uric acid level and ESRD incidence
During a median of 4.4 years of follow up [minimum,
1 month; maximum, 14.0 years] and a total of 1689
person-years of follow-up from the date of OLT through
April, 2010, 35 (11.7%) of the 300 patients under follow-
up were enrolled into the Medicare dialysis program.
The overall ESRD incidence rate was 20.7 events per
1000 person-years [95% confidence interval, 14.8–28.9
events/1000 person-years].
The unadjusted ESRD incidence rate (Table 4) was
similar among those with elevated uric acid compared to
those with lower uric acid. All adjusted associations were
null, whether uric acid was modeled as a dichotomous,
continuous variable or a quartile variable; and no inter-
actions by eGFR or diabetes were seen (Additional file 1:
Table S1). A Kaplan-Meier curve of survival according
to uric acid level confirmed no difference in ESRD
Table 3 Crude mortality rates and adjusted relative hazard of death after liver transplantation, according to mean uric acid level in






Adjusted b relative hazard of death
Characteristic p-value HR [95% C.I.] p-value
All Patients (n = 304) 0.04
Uric Acid <6.5 mg/dl 36 905 39.8 1.0 Reference
Uric Acid ≥6.5 mg/dl 53 914 58.0 1.4 [0.9, 2.2] 0.11
Uric Acid (+1 mg/dl increase) 1.07 [0.97, 1.18] 0.16
Stratified analysis
eGFR≥ 60 mg/min/1.73 m2 (n = 204) 0.46
Uric Acid <6.5 mg/dl 33 750 44.0 1.0 Reference
Uric Acid ≥6.5 mg/dl 24 530 45.2 1.0 c [0.6, 1.7] 0.95
Uric Acid (+1 mg/dl increase) 0.9 d [0.8, 1.1] 0.36
eGFR < 60 mg/min/1.73 m2 (n = 100) 0.005
Uric Acid <6.5 mg/dl 3 155 19.3 1.0 Reference
Uric Acid ≥6.5 mg/dl 29 383 75.6 3.7 c [1.1, 12.0] 0.03
Uric Acid (+1 mg/dl increase) 1.2 d [1.1, 1.4] 0.008
a Deaths per 1000 person-years of follow-up
b All models include age, gender, and time-dependent eGFR category
c p-interaction = 0.046
d p-interaction = 0.01
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Fig. 2 Kaplan-Meier plots of survival after orthotopic liver transplantation, according to mean uric acid level during the first 3 months after liver
transplantation and eGFR level at transplant, among all patients with up to 14 years of follow-up (Panel a) and up to 5 years of follow-up (Sub-
panel a); among those with eGFR≥60 ml/min (Panel b); and among those with eGFR<60 ml/min (Panel c)
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occurrence according to uric acid level (p = 0.65; figure
not shown).
Analyses stratified a priori by eGFR level and separ-
ately stratified a priori by diabetes status demonstrated
no subgroups with a significant association with uric
acid level. No significant interactions with eGFR level or
diabetes were present. Similar null findings were found
when uric acid was entered into the analogous multivari-
ate models as a continuous variable.
Other predictors significantly associated with ESRD
after OLT included diabetes, MELD score category,
eGFR category at time of OLT, and presence of hepator-
enal syndrome at time of OLT (Table 5). The presence
of hepatitis C was associated with ESRD (HR = 1.9), but
the association did not reach statistical significance.
End-stage renal disease was not significantly associated
with age, sex, race, cause of liver failure, hypertension,
hepatocellular carcinoma, mycophenolate mofetil use,
steroid use, or type of CNI used.
Discussion
This study examines the association between hyperurice-
mia and mortality, doubling of creatinine, and ESRD in-
cidence after OLT. We found that over a median follow
up period of 4.6 years, a serum uric acid level greater
than or equal to 6.5 mg/dL was independently associated
with an almost a four-fold increase in mortality, but only
among those with GFR < 60 mL/min/1.73 m2 (HR = 3.7,
p = 0.03), and not those with GFR ≥60 mL/min/1.73 m2.
The study also found that elevated UA levels are associ-
ated with doubling of creatinine among diabetics (HR =
2.2, p = 0.025), but not among diabetics. Although these
findings do not infer causality, they lay the groundwork
for future intervention studies among OLT patients with
both hyperuricemia and diminished renal function to es-
tablish whether mortality or progression of renal disease
in diabetics can be reduced with treatment of hyperuri-
cemia. Conversely, no association was found between
hyperuricemia and the development of ESRD, perhaps
owing to the small number of ESRD events with result-
ant limited power.
Although the association between increased mortality
and hyperuricemia has been reported in other transplant
populations such as renal [14] and heart transplant re-
cipients, [19] this is the first study to investigate the ef-
fect of hyperuricemia on mortality among orthotopic
liver transplant recipients. Dahle et al. reported that in
renal transplant recipients, a J-shaped association exists
Table 4 Crude rates and adjusted relative hazards of doubling of creatinine and USRDS-documented progression to end-stage renal





Adjusted b Relative Hazard
Characteristic p-value HR [95% C.I.] p-value
Outcome: doubling of creatinine
All Patients (n = 300) 0.24
Uric Acid <6.5 mg/dl 81 361 224.3 1.0 Reference
Uric Acid ≥6.5 mg/dl 99 370 267.3 0.9 [0.7, 1.3] 0.70
Uric Acid (+1 mg/dl increase) 0.96 [0.90, 1.03] 0.30
Analysis stratified by diabetes
Non-diabetics(n = 221) 0.86
Uric Acid <6.5 mg/dl 63 252 249.5 1.0 Reference
Uric Acid ≥6.5 mg/dl 69 268 257.2 0.8 c [0.5, 1.1] 0.15
Uric Acid (+1 mg/dl increase) 0.92 d [0.84, 0.99] 0.04
Diabetics(n = 79) 0.014
Uric Acid <6.5 mg/dl 16 100 160.7 1.0 Reference
Uric Acid ≥6.5 mg/dl 29 85 341.1 2.2 c [1.1, 4.3] 0.025
Uric Acid (+1 mg/dl increase) 1.1 d [1.00, 1.31] 0.049
Outcome: Progression to ESRD
All Patients (n = 300) 0.31
Uric Acid <6.5 mg/dl 16 844 18.9 1.0 Reference
Uric Acid ≥6.5 mg/dl 19 845 22.5 0.9 [0.4, 1.7] 0.70
a Events (doubling of Scr or progression to ESRD, respectively) per 1000 person-years of follow-up
b All models include age, gender, and time-dependent eGFR category
c p-interaction = 0.061
d p-interaction = 0.042. No interactions with eGFR or diabetes were seen in the association between UA and ESRD, and no interactions with eGFR were seen for
doubling of creatinine
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between serum uric acid level and cardiovascular and
all-cause mortality [14]. Our study did not identify such
a J-shaped association between uric acid level and mor-
tality, although it should be noted that the association of
the lowest uric acid levels with mortality reported by
Dahle was statistically non-significant (RH = 1.31; p =
0.18). Similar to our study, however, Arora, et al., found
increased mortality among heart transplant patients with
elevated serum uric acid levels at 1 year, [19] although
they did not stratify the association according to eGFR
level. The cause of the observed effect modification by
eGFR level is not known, although one may hypothesize
that patients with low eGFR may be more prone to
hyperuricemia-induced acceleration of endothelial and
vascular injury. Importantly, since uric acid level in-
creases with decreases in renal function, it is difficult to
disentangle the association of uric acid with outcomes
associated with decreased renal function. While our
retrospective study adjusted for time-dependent eGFR,
such adjustment may be incomplete owing to gaps in
renal function measurements in clinical practice. A pro-
spective cohort study which measures renal function
regularly on all patients should be performed in the fu-
ture to provide the strongest evidence of the role of uric
acid in these outcomes.
The association between hyperuricemia and mortality
has been postulated to be related to increased cardiovas-
cular events in those with high uric acid levels [20].
Studies in non-transplant populations, however, have
not demonstrated such an association. The Framingham
Heart Study group concluded that uric acid is merely a
marker of increased risk for cardiovascular disease due
to its association with hypertension, hyperlipidemia and
Fig. 3 Kaplan-Meier plot of doubling of serum creatinine, according
to mean uric acid level during the first 3 months after liver
transplantation, and stratified by diabetes status (Non-diabetics,
Panel a; and Diabetics, Panel b)
Table 5 Predictors of USRDS-documented end-stage renal disease
(ESRD) after liver transplantation
Adjusted b Relative
Hazard of ESRD
Characteristic HR [95% C.I.] p-value
Diabetes
No 1.0 Reference
Yes 2.6 [1.3, 5.2] 0.005
MELD score category
< 20 1.0 Reference
20–29 2.2 [1.0, 4.7] 0.04
≥ 30 2.6 [1.0, 6.4] 0.04
p-trend = 0.02
MELD Era
Pre-MELD era (<2/02) 1.0 Reference
MELD era (≥2/02) 2.0 [0.8, 5.1] 0.13
eGFR category at OLT
≥ 90 1.0 Reference
60–89 2.6 [0.9, 7.0] 0.07
30–59 2.6 [1.0, 7.0] 0.06




Yes 3.8 [1.4, 10.3] 0.01
Hepatitis C virus infection
No 1.0 Reference
Yes 1.9 [1.0, 3.9] 0.065
Calcineurin inhibitor useb
Tacrolimus 1.0 Reference
Cyclosporine 1.0 [0.4, 3.1] 0.94
Type not known 0.7 [0.3, 1.6] 0.40
a All models include age, gender, diabetes, and time-dependent eGFR
category. Note: ESRD was not significantly associated in the adjusted
models with age, sex, race, cause of liver failure, hypertension,
hepatocellular carcinoma, mycophenolate mofetil use, or steroid use
b The “None” category for CNI use had too few observations for
inclusion in the model
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impaired glucose metabolism [21]. In our study, infor-
mation regarding cause-specific mortality was not avail-
able and hence we cannot determine if the increased
mortality associated with hyperuricemia in the low-
eGFR group was related to cardiovascular events.
The present study found that OLT recipients with
GFR < 60 mL/min/1.73 m2 had significantly higher mean
serum uric acid in the post-transplant period compared
to recipients with GFR ≥ 60 mL/min/1.73 m2. This in-
verse association emphasizes the central role of the kid-
ney in urate clearance and the dose–response
association between urate levels and renal function in
the OLT population, which renders the disentanglement
of the two effects on renal and other outcomes
challenging.
Our study demonstrated no overall association be-
tween UA level and the incidence of ESRD or doubling
of creatinine. However, we did find that UA level pre-
dicts doubling of creatinine among diabetics. Historic-
ally, uric acid has been identified only as a marker of
renal damage. However, some observational studies have
raised the possibility that the relationship between renal
function and uric acid may be more complex [22, 23].
Uric acid was hypothesized to play a role in causing
renal dysfunction by induction of afferent arteriolopathy,
inflammation, and activation of the renin-angiotensin
system [24]. Supporting this notion is the observation
that renal function improves among liver transplant pa-
tients with gout and hyperuricemia after treatment with
allopurinol, a urate-lowering medication [3]. While this
study cannot assess the mechanism for the observed
interaction with diabetes, it does support the hypothesis
that UA may increase the deleterious effect of diabetes
on the kidney.
The incidence of post-OLT ESRD has been previously
estimated at 12.8 and 14.5 per 1000 patient-years in the
pre- and post-MELD era, respectively [25]. The overall
incidence of ESRD in our cohort was higher, at 20.7 per
1000 years, though only 35 patients progressed to ESRD.
Some other studies have suggested various factors po-
tentially contribute to the progression of renal disease
and ESRD development in patients after OLT, including
hyperuricemia [26]. Several studies in the general popu-
lation have demonstrated an association between hyper-
uricemia and ESRD [9, 27] but others did not find this
association, especially in advanced stages of CKD (stage
III-V) [28]. The small number of ESRD events in our
study and the resultant low statistical power may par-
tially explain the lack of association between hyperurice-
mia and ESRD incidence in our cohort, although the
associations between uric acid (as a dichotomous, quar-
tile, and continuous variable) and ESRD incidence were
all very close to the null. The factors associated with in-
creased ESRD incidence in our study included lower
eGFR, diabetes, higher MELD score, and the presence of
hepatorenal syndrome, all of which are pathophysio-
logically plausible.
Calcineurin inhibitors, particularly cyclosporine, have
been cited as a factor that could lead to hyperuricemia
after organ transplantation [29]. Cyclosporine can cause
hyperuricemia by increasing net tubular urate reabsorp-
tion [30] or decreasing the glomerular filtration of uric
acid [31]. However, our study did not find associations
between CNI sub-type and either uric acid level after
OLT or ESRD incidence, perhaps because the frequency
of cyclosporine use was less than 10% in this cohort and
we were not able to take the effects of CNI use on UA
fully into account. Use of allopurinol to lower uric acid
levels in this cohort was also very low, so use of urate-
lowering medications is unlikely to have confounded
these results.
A number of plasma membrane transporter proteins
participate in uric acid handling. Among the various
transporter proteins that play the most important role in
uric acid reabsorption are URAT1 protein which is only
expressed in human kidney on the brush border mem-
brane of the proximal tubule and GLUT9 which is
expressed in the basolateral membrane of the proximal
tubule but also the basolateral membrane of hepatocytes
[4]. Studies on diverse patients’ population have identified
mutations or allelic variants in genes encoding for specific
urate renal transporters that are associated with hyperuri-
cemia as a result of urate under-excretion [32–34]. In our
study, genetic testing for these conditions was not per-
formed. However, this may be worthwhile in future studies,
since these genes could be potential targets for treatment.
The present study is limited by lack of cause-specific
mortality during the follow-up period. Nevertheless, this
study is important, as it is the only study to examine the
impact of hyperuricemia on total mortality, doubling of
creatinine and incidence of ESRD among liver transplant
patients. Second, uric acid levels were only reliably avail-
able for 3 months post OLT and we could not exclude
the possibility of residual confounding. Nonetheless, the
results of this study could provide a rationale for inter-
ventional studies assessing the role of early treatment of
hyperuricemia in liver transplant recipients and its effect
on mortality, particularly among those with renal dys-
function; and its effect on progression of renal disease
among those with diabetes. Recently, treatment of
asymptomatic hyperuricemia post kidney transplantation
was associated with a substantial benefit in patient and
graft survival [15]. Another limitation is that GFR esti-
mating equations do not perform very well in patients
with liver disease, thus resulting in the potential of some
misclassification of renal status above and below the
eGFR cut-point value of 60 mg/min/1.73 m2. Also, the
14-year follow-up includes a period during which
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transplant practices have changed, the effects on out-
comes of which were likely not fully captured in this
retrospective study. We also did not have information
on type of CNI used in 23% of the cohort, which could
bias the findings related to CNI use in an unknown dir-
ection. Lastly, the limitation of CNI subtype to 2003 and
later may result in an underestimation of the use of
cyclosporine, since some patients on cyclosporine before
2003 may have switched to tacrolimus. If this occurred
to a significant degree, this would bias the association of
CNI subtype with ESRD incidence towards the null.
Conclusions
In conclusion, mean serum uric acid levels are elevated
after orthotopic liver transplantation, and are signifi-
cantly associated with eGFR category in the OLT popu-
lation. Hyperuricemia is independently associated with
mortality, particularly among liver transplant patients
with GFR less than 60 mL/min/1.73 m2, and associated
with doubling of creatinine among diabetics, but is not
associated with ESRD incidence.
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